Psychomotor slowing in hepatitis C and HIV infection

Hans-Jürgen von Giesen1, Tobias Heintges, Naghme Abbasi-Boroudjeni

  • 1Department of Neurology, Hepatology and Infectious Diseases, Heinrich Heine University, Düsseldorf, Germany. giesenhj@uni-duesseldorf.de

Insights

Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) can affect cognitive and motor functions. This study found psychomotor slowing in both HIV and HCV patients, with prolonged reaction times specifically in coinfected individuals.

Area of Science:

  • Neuroscience
  • Infectious Diseases
  • Neurology

Background:

  • Both Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) can impact the central nervous system, potentially causing cognitive and motor deficits.
  • Limited data exists on cognitive function and virtually no data on motor performance in patients coinfected with HIV and HCV.

Purpose of the Study:

  • To assess and compare cognitive and motor performance in patients with HIV/HCV coinfection.
  • To provide data on the neurological impact of HIV and HCV infections, individually and combined.

Main Methods:

  • Compared three groups: HIV-seropositive/HCV-seronegative (n=43), HIV/HCV-coinfected (n=43), and HIV-negative/HCV-positive (n=44).
  • Utilized neuropsychological testing and electrophysiological assessments of basal ganglia-mediated motor function.

Main Results:

  • No significant differences were observed in intelligence, attention, memory, HIV dementia scale, or most somatic/psychiatric complaints across groups.
  • HIV-negative/HCV-positive patients reported fewer affective disorders and lower depression scores.
  • All three groups exhibited pathological slowing of rapid alternating movements and prolonged contraction times; only HIV/HCV-coinfected patients showed significantly prolonged simple reaction times.

Conclusions:

  • Clinically asymptomatic HIV-positive and HCV-positive patients may exhibit affective disturbances and significant psychomotor slowing.
  • The predictive value of these findings for disease progression requires further investigation, particularly in HCV-positive and coinfected individuals.
Abstract

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...